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Abstract
Background: Compromised bone stock and heavily impaired structural integrity after multiple endoprosthetic revision
surgeries can lead to a comparable condition as encountered in musculoskeletal tumor surgery. Total femoral
replacement (TFR) can restore femoral integrity and allow patients to resume ambulation. Even though several
authors reported their results of TFR, so far many questions are still on debate: Which patients are at risk to
experience low functional outcome? Do complications and clinical outcome after TFR depend on the indication
for the surgery (e.g. periprosthetic fractures or aseptic loosening) or the age of the patients? The purpose of the
present study was to compare complication rates after TFR performed with modular total femur prosthesis MML
(Fa. ESKA/Orthodynamics) in patients without malignant disease.
Methods: We conducted a retrospective chart review and functional investigation of patients treated with a TFR
for non-oncologic conditions from 1995 to 2015 and a minimum follow-up of 2 years. Complications were recorded
according to the Henderson-Classification; outcome was evaluated with established clinical scores. The indication for
TFR was periprosthetic fracture (Group A, n = 11) or aseptic loosening (Group B, n = 7) with massive bone defect of the
femur deemed unsuitable for conventional arthroplastic or biologic reconstruction.
Results: Eighteen patients matched the inclusion criteria and could be investigated clinically after a mean follow-up of
80 months (range: 28–132). Before TFA, all patients had previously undergone multiple operations (range: 1–8). The
overall failure rate for any reason was 72% (n = 13/18), leading to a total of 37 surgical revisions with total exchange of
TFR in 22% (n = 4/18). Most common failure mechanism was Type I (soft tissue), followed by Type IV (infection) and
Type III (mechanical failure). According to Enneking’s functional evaluation method (MSTS-Score), the function ranged
from 1 to 15 with a mean of 10 ± 4 out of 30.
Conclusion: TFR is a salvage procedure to restore mechanical integrity and regain functional ability after extensive
femoral bone loss. Outcome of the patients in the present study did mainly depend on the age at reconstruction and
not on the indication for TFR.
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Background
With increasing numbers of primary total hip and total
knee arthroplasty, largely attributed to demographic
changes in our society, endoprosthetic revision surgeries
will become even more important in orthopedic surgery.
Yet it is not only the sheer number but also the severity
of revisions with massive, segmental bone loss and highly
compromised soft tissues that will represent a major chal-
lenge to the future of joint replacement (Fig. 1).
In the lower extremity, the primary function is to
support body weight and allow ambulation, durable re-
construction of bone defects after multiple revision sur-
geries is of major interest to preserve its function. Many
surgical options for the reconstruction and stabilization of
massive bone defects have been described and include,
amongst others, the use of tumor endoprostheses [1]. The
success of this procedure has come a long way, from
custom-made monobloc devices to modular megaprosth-
eses using the most modern implant techniques and sur-
face technologies, including antibacterial coatings [2]. The
most extreme use of modular megaprosthetics is consid-
ered to be the replacement of the whole femur, including
the hip and knee joint. Total femoral replacement (TFR)
can restore femoral integrity and allow patients to resume
ambulation, although at a compromised level. Neverthe-
less, this compromised functional capacity is deemed su-
perior to that achieved after hip exarticulation. There have
been some reports analyzing functional outcome after
treatment with TFR for aggressive musculoskeletal tumors
[3–8], but only few for non-oncologic indications [1, 9–12].
The aim of this study was to retrospectively review the
mid-term results after non-oncologic TFR for severe
bone loss from one orthopedic center (Technical
University Munich, Munich, Germany).
Methods
This study was reviewed and approved by the Medical
Ethical Committee at the Klinikum rechts der Isar
(Technical University of Munich) and research was car-
ried out in compliance with the Helsinki Declaration.
Written informed consent was obtained from all pa-
tients included in the study.
We retrospectively reviewed our institution’s database
of patients who underwent a surgical procedure with re-
section of the femur due to bone tumors or failed revi-
sion arthroplasties and reconstruction using TFR from
January 1995 to January 2015. Reconstruction was carried
out with a modular total femur prosthesis (Type MML,
Fa. ESKA/Orthodynamics, Luebeck, Germany) utilizing
a standard ceramic head with 32 mm diameter, a non-
cemented, spongy metal structured cup with conventional
polyethylene liner (CL Type 2000 Plus or cranial socket,
Fa. ESKA/Orthodynamics, Luebeck, Germany) and a
hinged constrained total knee system (Fig. 1c, d). TFR was
performed with the patient placed in a supine position
and a lateral approach to the femur. After excision of the
remaining femur and the prosthetic device (acetabular
cup was left in place if no signs of loosening were evident),
the total femur prosthesis was inserted with first prepar-
ation of the acetabulum, then the knee, and at the end
connection of both parts with the diaphyseal modules.
Hip abductor muscles were fixed to the trochanteric part
of the TFR with non-resorbable suture material. Routinely,
a 10-day antibiotic treatment with cefuroxime was
given postoperatively. Antithrombotic prophylaxis with
low-molecular-weight heparin was administered for six
weeks. Physiotherapy was conducted for the first 3 months.
It consisted of exercises aimed for increasing circula-
tion to the legs and feet to prevent thrombosis. Muscle
Fig. 1 a, b X-ray of a patient with periprosthetic fracture at the level of the left femur and concomitant destructive osteoarthritis of the knee.
c, d Reconstruction of femoral integrity was performed with total femoral replacement with MML-Prosthesis (acetabular cup was left in place
due to no signs of loosening)
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strengthening and mobilization of the hip was a focus
of the therapy. Patients were allowed to perform exer-
cises in the water after definite wound healing. Accord-
ing to the post-op standard, partial weight bearing
within the first 4 weeks after surgery was allowed. We
identified 39 patients (39 implants) with TFR. 16 pa-
tients were excluded due to an oncologic indication for
their TFR. Of the 23 remaining patients, 3 were ex-
cluded due to unattainability, 2 due to follow-up of less
than 24 months. Thus, 18 patients were included in our
study for clinical assessment and survival analysis of the
TFR (Fig. 2). Demographic data of the cohort are given in
Table 1. Patients were subdivided into Group A and B ac-
cording to the indication for TFR: Group A consisted of
patients with a periprosthetic fracture (n = 11; mean age at
reconstruction with TFR 77 years (±8 years), range 67–
90), Group B had surgery for aseptic loosening (n = 7;
mean age at reconstruction with TFR: 79 years (±7 years),
range: 70–88). This subdivision was carried out on the as-
sumption that indication for TFR might influence its out-
come [13]. Patients were routinely followed after TFR at
least once a year after the first year from reconstruction
with TFR. Patients living far away from our clinic were
contacted and asked to present for participating at the
study. Hence, at the latest follow-up (Table 2), details of
the postoperative course (i.e. complications), and scores
analyzing the current function (MSTS score, Harris Hip
Score (HHS), Oxford Knee Score (OKS), SF-12-health sur-
vey) were evaluated. VAS values are collected routinely prior
every surgical intervention at our clinic, so that this score
was available also prior reconstruction with TFR. All other
functional scores were only collected at latest follow-up.
Complications were classified according to the five modes of
failure for megaprostheses proposed by Henderson et al.
[14]: soft tissue failure (Type I), aseptic loosening (Type II),
structural failure of implant and/or bone (Type III), in-
fection (Type IV), and tumor progression (Type V).
Statistics
The survivorship analysis was performed using the Kaplan-
Meier survivorship method. All data are reported as the
mean and standard deviation, where applicable. Com-
parisons of patient-reported outcomes were performed
using a t-test. Statistical significance was set at p < 0.05.
Correlations between numerical data were done with
linear regression analysis, and Pearson’s correlation co-
efficient (r) is reported. Statistical analysis was per-
formed using SPSS 2.0 (IBM, Armonk, NY, USA).
Results
Indication for TFR
Prior to defect reconstruction with TFR all patients had
a history of at least one orthopedic/traumatologic surgical
procedure (i.e. nail, primary hip and/or knee prosthesis or
mega-prosthesis). Specific indications for TFR of either
group are given in Table 2. In Group A, 44 revision sur-
geries prior to TFR were reported in a total of 11 patients,
leading to a total revision number of 4 ± 2 per patient
(range: 1–8). In Group B, seven patients had a history of a
total of 12 revision surgeries prior to their TFR, leading to
a total revision number of 2 ± 1 per patient (range: 1–3).
Complications
The average time from surgery to the development of a
complication was 14 months (range: 1–105 months) with
an average time to complication for Group A of 26 months
(range: 11–60 months) and 6 months (range: 1–9 months)
for Group B. Average time to occurrence of failures ac-
cording to the Henderson-Classification varied depending
on the different types. Type I was observed in 11 patients
Fig. 2 Constellation of total cohort and patients included in the study group
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at an average time of 12 months (range: 4–54 months)
after surgery; Type III was observed in 2 patients at an
average of 34 months (range: 14–48 months) after surgery;
Type IV was observed in 8 patients at an average of
50 months (range: 4–105 months) after surgery. A Type II
failure was not observed in any of the patients. Type V
failure (tumor recurrence) was not eligible for this cohort
of non-oncologic patients, respectively. Overall, there were
28 implant-related complications according to Henderson
in 13 patients with all of these being either Type I, III or
IV failures (Table 3). Complications led to 37 revision
surgeries (implant-related and implant-independent).
Analysis of complication-types
Type I Recurrent hip dislocations were observed in 5
patients (Group A: 3; Group B: 2), whereof all
patients initially underwent closed reduction
and conservative treatment. 2 patients had to
undergo three revision surgeries subsequently
(1× replacement of the head, 1× replacement
of inlay and head, 1× cup replacement).
Wound healing problems were observed in 11
cases (Group A: 5; Group B: 6) with the need
of 11 surgical interventions in 10 patients.
Conservative wound treatment was successfully
performed in 1 case. Painful knee arthrofibrosis
with a limited range of motion was observed in
1 case of either group: 1 patient (Group A) was
revised with a knee arthrodesis, 1 patient
(Group B) received successful joint
mobilization (brisement forcé) under general
anesthesia.
Type III In either group 1 patient sustained a
mechanical failure of its TFR. In both
patients, a failure of the hinge-mechanism of
the fully constrained knee module with
Table 2 Main data of patients regarding medical history and functional outcome according to MSTS-score. Indication for TFR was
periprosthetic fracture (Group A) of aseptic loosening (Group B)






Follow-up (months) MSTS Score
A/1 DFP and HP 76 3 132 15 Group A: 10 (±5)
A/2 DFP and HP 67 5 45 15
A/3 PFP and KP 81 7 78 10
A/4 DFP and HP 76 3 79 11
A/5 Nail and HP 71 3 79 12
A/6 HP 69 2 99 14
A/7 HP and KP 70 7 87 13
A/8 KP 84 1 54 4
A/9 KP 86 8 45 1
A/10 HP and KP 74 1 85 8
A/11 Nail and KP 90 4 111 6
B/12 HP and KP 79 1 58 8 Group B: 10 (±4)
B/13 KP 70 2 67 15
B/14 DFP 85 2 121 5
B/15 HP and KP 88 1 28 7
B/16 HP 70 1 109 9
B/17 HP 83 2 76 15
B/18 HP and KP 77 3 80 10
Mean 78 3 80 10
Standard deviation 7 2 28 4
MSTS musculoskeletal tumor society (MSTS-score is given as patient-specific mean score and group-specific mean score), HP hip prosthesis, KP knee prosthesis,
DFP distal femoral prosthesis, PFP proximal femoral prosthesis
Table 1 Demographics of patients after TFR
Demographic Mean ± SD
Age (years) 78 ± 7 (range, 67–90)
Sex (Male/Female) 4/14
Height (cm) 162 ± 10
Weight (kg) 74 ± 11
BMI (kg/m2) 27.5 ± 4.6
Mean follow-up (months) 80 ± 28 (range, 28–132)
Side of TFR (Right/Left) 10/8
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breakage of the bolt was observed. Both knees
were revised with an exchange of the inlay
and the hinge-mechanism.
Type IV Septic complications of the TFR were
observed in 8 patients (Group A: 3; Group B:
5) with a total of 19 revision surgeries. One
patient had to undergo only 1 revision, all
others at least 3. Four patients needed total
(all components), 4 patients partial exchange
of the TFR. All patients had antibiotic
treatment for 6–12 weeks after the last
surgical intervention for infect eradication, no
patient needed lifelong suppression therapy.
The microbes detected were 6×
Staphylococcus epidermidis, 1×
Propionibacterium acnes, 2× Staphylococcus
aureus, 2× Enterococcus faecalis, 1×
Micrococcus luteus (some patients hat
multiple bacteria).
Implant survival analysis
Mean follow-up of patients was 80 ± 28 months (range:
28–132). Implant failure was defined as partial or
complete exchange of the megaprosthesis due to implant-
related complications. Implant failure was detected in 44%
(n = 8/18) of cases at five years, and 56% (n = 10/18) al lat-
est follow-up. Only 5 patients had an uneventful implant-
survival without any kind of revision surgery throughout
the study period.
Clinical outcome
Overall, patients in this series had a mean VAS-score
preoperatively of 5.9 (Group A: 5.9; Group B: 5.9) and
postoperatively after TFR of 3.6 (Group A: 3.5, Group B:
3.6). The differences were significant (p < 0.001) compar-
ing pre- and postoperative VAS-scores.
Clinical outcome data computed by MSTS score, HHS
and OKS, as well as results of SF-12 analysis are given in
Tables 2 and 4. There were no differences neither be-
tween the groups nor between the subgroups. Linear re-
gression analysis between age/revisions prior TFR and
clinical outcome (MSTS-score) revealed a moderate nega-
tive correlation for age (r = −0.69) and no correlation for
prior revisions (r = −0.05).
Discussion
Reconstruction of massive bone defects of the femur after
failed revision arthroplasty represents a challenge for ortho-
pedic surgeons. TFR can restore femoral integrity and allow
patients to resume ambulation, albeit at a compromised
level. Usually, this reduced functional capacity is superior to
that achieved after hip exarticulation [3]. This study an-
alyzed the clinical and functional results of 18 TFRs of
patients with a history of failed revision arthroplasty ei-
ther due to periprosthetic fractures (Group A, n = 11)
or aseptic loosening (Group B, n = 7). To our knowledge,
there are no published case series using a standardized
failure-mode classification with the presented numbers
regarding TFRs performed with the MML-System (Fa.
ESKA/Orthodynamics); therefore, we investigated the
TFRs of a single centre University Institute for implant
survival, functional outcomes and different types of
complications.
Table 3 Number of failures in this series as classified according to Henderson et al. [14]; Note: 28 complications were found in 13
patients (some patients had multiple failures)
Type of failure Group A (n = 11) Group B (n = 7) Total number of complications
I (soft tissue failure) 3 dislocations
5 wound healing problems
1 arthrofibrosis
2 dislocations





II (aseptic loosening) - - -
III (structural) 1 breakage of bolt 1 breakage of bolt 2
IV (infection) 3 5 8
V (tumor progression) - - -
Total 13 15 28
Table 4 Functional outcome results of both groups




HHS Mean score 43 (16–70) 38 (21–60)
Pain 23 (10–37) 20 (11–32)
Function 9 (0–14) 6 (0–11)
Activity 5 (0–10) 5 (1–10)
Contractures 4 (3–4) 3 (3–4)
motion 3 (2–4) 2 (2–4)
OKS Mean score 14 (4–26) 17 (10–25)
SF-12 Physical subdomain 27 (21–36) 27 (22–35)
Mental subdomain 38 (27–61) 38 (28–63)
HHS (harris hip score): <70: poor; 70–79: fair; 80–89: good; 90–100: excellent,
OKS (oxford knee score): <19: poor; 20–29: fair; 30–39: good; 40–48: very good,
SF-12 (short form 12 health survey): healthy controls > 50
p < 0.05 = significant (*)
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A main finding of the present study is that no differ-
ences were observed in clinical outcome between the
groups (Table 2). Subdivision of our cohort into two
groups was performed on the assumption that indication
might influence pre- and postoperative function [13].
Periprosthetic fractures cause acute onset of symptoms
with the necessity of immediate treatment within a short
period, whereas aseptic loosening usually goes along
with a chronically painful dysfunction of the implant
and the need for revision only in cases without improve-
ment of symptoms after failed conservative treatment. In
fact, we found that preoperative VAS-scores were similar
in both groups without significant differences. Addition-
ally, postoperative MSTS-scores, OKS and SF-12 health
survey showed no differences between the groups. Func-
tional outcome measurement according to the MSTS-
Score revealed an average value of 10 (33%) in the
present study and therefore the results were inferior in
comparison to other studies investigating TFR after
failed revision arthroplasty with average results between
59-77% (Table 5). Nevertheless, some specifications re-
garding individual cases of both groups are necessary for
adequate interpretation of these values: Two patients
(A8 and A9, Table 2) suffered from a strongly deterio-
rated health preoperatively with advanced dementia.
Additionally, patients of the present study were signifi-
cantly older compared to patients of other studies
(Table 5). These factors influence the MSTS-score and
might at least partially explain the differences between
the groups. In fact, other authors found a significant in-
fluence of age at time of implantation and number of re-
visions prior to TFR on postoperative TFR outcome [13,
14]. In this regard, the results of the present study show
some discrepancy with these findings. In our cohort,
both groups were very similar regarding age (Group A:
77; Group B: 79; p > 0.05) but not regarding revisions
prior to TFR (Group A: 4 ± 2; Group B: 2 ± 1; p < 0.05).
In sum, indication (periprosthetic fracture vs. aseptic
loosening) did not influence clinical outcome of TFR in
the present study. Linear regression analysis between
age/revisions prior TFR and clinical outcome revealed a
moderate negative correlation for age, which means
there is a tendency for older patients to go with low clin-
ical outcome.
HHS as a well-established hip score has so far only
been used by Berend et al. to evaluate hip function in
TFR [10]. In his series, an average value of 70 was found.
In the present study, an overall score of 41 was detected
with again no significant differences between the groups
(Group A: 43; Group B: 38). Evaluation of TFR cannot
be compared to results from primary or conventional re-
vision THA. The OKS has so far not been evaluated for
TFR. In the present study, a rather low average value
(32%) was found, with again no significant differences
between the groups (A: 30%; B: 35%). As with HHS,
OKS seems not to be an appropriate tool to evaluate
functional outcome after TFR. In summary, pain mea-
sures revealed a significant reduction of pain after TFR
compared to preoperative values. Function with mobility
is nevertheless reduced in both groups. This finding is
supported by the physical SF-12 survey score (Table 4).
The mental SF-12 survey scores were similar in both
groups, stating good acceptance of the TFR. Patients of
the present study communicated clearly that regain of
partial mobility and reduction of pain are the most im-
portant items to achieve satisfaction after TFR. Other
authors have already published this finding [10, 11].
Another main finding of the present study was a 72%
overall complication rate in our patients treated with
TFR (Fig. 3). It has to be stated that none of the included
patients (n = 18) in the present study had a primary defect
reconstruction with TFR. In fact, 56 revision surgeries
were performed in the study population prior to implant-
ation of TFR. This is important as postoperative complica-
tions after TFR might be at least partly related to prior
surgical procedures. Despite the high complication rates,
only 4 TFRs had to be completely replaced. Most of the
postoperative revision surgeries had to be performed due
to soft tissue problems (Type I failure) which were de-
tected in 11 cases, necessitating 16 surgical revisions. The
most common cause for Type I failure was aseptic wound
dehiscence (n = 11), followed by hip dislocation (n = 5)
and knee arthrofibrosis (n = 2). In the literature, reported
rates vary between 0% and 45% [3–5, 7, 11] for Type I
complications. It is known from large series with primary
hip arthroplasty that 75% of dislocations occur within the
first two months after implantation [15]. In our study, this
was observed in 67% of dislocations. To prevent hip dis-
location in cases of residual trochanteric bone or viable
tendinous abductor structures we preferred direct attach-
ment to the endoprosthetic implant with non-resorbable
sutures. Promising results regarding hip stability can be
obtained if tripolar cups are used [2, 3, 8]. Where applic-
able, tripolar cups are now performed routinely in our
clinic to reduce rates of hip dislocation.
Aseptic loosening (Type II failure) in megaprostheses
was reported in the literature with a rate ranging from 2.4
to 15.4% for cemented stems [16–19] and from 0% to 8%
for cementless implants [20–23]. In our series, no aseptic
loosening was found and therefore confirmed the data of
the literature with a low incidence of this type of failure in
TFR [5, 11]. Contrary to proximal or distal femoral pros-
theses (PFP/DFP), TFR implantation does not have to rely
on diaphyseal stem fixation but uses common techniques
of THA and (fully constrained) TKA with a standard ace-
tabular cup and tibial meta-diaphyseal stem fixation. This
might explain better results of TFR regarding aseptic loos-
ening compared to PFR and DFR.
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Structural failure (Type III failure) was observed in
two patients in our series. The structural failure was a
prosthetic breakage at the level of the hinged-knee joint.
In both cases, the affected prosthetic parts were surgi-
cally exchanged and no further material failure was ob-
served. In the literature, the incidence of prosthetic
component breakage in megaprostheses ranges between
0% and 7.7%, with lower incidences in TFR compared to
distal or proximal femoral replacement. Again, this might
be accounted for by an absence of diaphyseal stems in
TFR which are a known weak spot in modular mega-
prostheses [24]. Other authors conclude, reduced mobility
and activity in this population as a reason for lower rates
of structural failure probably due to lesser activity in this
population [16, 18, 19, 21–23].
Type IV failure (deep infection) was observed in eight
out of 18 patients (44%) in our series. These data are
considerably higher compared to infection rates described
in the recent literature with a reported range from 0 to
35% in TFR [3–5, 7–9, 11]. A possible explanation for
these high infection rates is the number of revision surger-
ies prior to implantation of TFR (56 in 18 patients). Add-
itionally, it has to be mentioned that all patients with deep
infection of the TFR had a septic complication of their
prosthesis prior to implantation of their TFR. It is known,
that reinfection rate after cured deep infection is consider-
ably higher than infection rates of primary prostheses [25].
Another explanation may be found considering the demo-
graphic data of our cohort showing that our patients are
significantly older compared to studies with TFRs from
oncologic patients [13]. Nevertheless, despite the high
infection rates permanent eradication of infection was
achieved in all cases. This might be due to our aggres-
sive and early surgical interventions whenever deep in-
fection was present leading to a total of 19 revisions in
our cohort. In four patients complete exchange of TFR,
in all other patients partial exchange of the modular
parts of the TFR was performed. One patient had to
undergo only one revision, all other patients needed
multi-stage revision surgeries to eradicate infection. All
patients had antibiotic treatment for 6–12 weeks after
the last surgical intervention for infect eradication, no
patient needed lifelong suppression therapy.
The implant-independent failure mechanism Type V
(tumor progression/recurrence), was never observed in
our cohort of patients, as defined in our inclusion criteria.
For oncologic indications of TFR, authors describe rates
between 5 and 20% [3–5, 7].
This study has some limitations that bear discussion.
At first, the retrospective study design is subject to recall
and selection bias. The number of patients is small and
statistical analysis therefore difficult. Nevertheless, due to
the rare indication for this procedure our series is com-
parable to studies published earlier. Secondly, this study
lacks a control group. Thus, we cannot directly com-
pare our results with other types of implants or biologic
reconstructions.
Conclusion
Preservation of lower limb integrity and immediate stabil-
ity to allow early mobilization are the primary benefits of
TFR. Nevertheless, patients requiring this salvage tech-
nique are usually severely debilitated and their associated
perioperative morbidity must be taken into consideration.
The retrospective analysis of our series confirmed the high
incidence of implant-related complications and failures in
TFR with infection and soft tissue failure as the most fre-
quent modes of complications. Implant survival of 56% at
5 years was observed, and seems not to be affected by ini-
tial diagnosis for TFR (periprosthetic fracture vs. aseptic
loosening). Non-oncologic patients who receive TFR as
a form of end-stage revision arthroplasty have to be in-
formed about the less favorable results compared to
“conventional” revision joint arthroplasty and TFR for
oncologic indications. The ultimate failure of TFR most
commonly results from persistent periprosthetic infection
and might eventually require hip exarticulation. Therefore,
TFR requires very strict indications and potential benefits
and burdens of this procedure have to be evaluated indi-
vidually. Nevertheless, TFR sometimes remains the only
viable option to allow functional limb salvage in rare cases
of non-reconstructable periprosthetic fracture situations
and extensive bone loss caused by repeated endopros-
thetic revision surgeries.
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